CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 188 enrolled
Drug / intervention
MEDI3902 +1 moredrug
Likely dose
MEDI3902 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02696902
NCT02696902Phase 2Completed
CompareCT.gov

A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa

MedImmune LLC·interventional·Posted Mar 2, 2016·Updated Feb 4, 2021

In Brief

A Phase 2 clinical trial evaluating MEDI3902 and Placebo for Pseudomonas Aeruginosa. Completed, enrolled 188 participants across 78 sites in 14 countries.

Detailed Summary

Clinical trial looking to evaluate the efficacy and safety of MEDI3902 in mechanically ventilated participants for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPseudomonas Aeruginosa
CountriesAustria, Belgium, Croatia, Czechia, France, Greece, Hungary, Ireland, Israel, Portugal, Spain, Turkey (Türkiye), United Kingdom, United States
CollaboratorsInnovative Medicines Initiative, Antibacterial Resistance Leadership Group, National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2, 2016
Enrollment StartMar 25, 2016
Primary CompletionDec 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.3 years ago

Interventions

MEDI3902drug

Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.

Placeboother

Participants will receive a single IV dose of placebo matched to MEDI3902.